Drug Trial Radar · NCT03487276
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Last checked: Nov 19, 2026Latest source record: Apr 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
179
Actual
Start
Feb 26, 2018
Primary completion
May 27, 2019
Study completion Jan 27, 2020
Sponsor
- Lead sponsor
- InflaRx GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Quintiles, Inc.
- First posted
- Apr 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of moderate to severe hidradenitis suppurativa.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
IFX-1Drug
Single IV infusions of IFX-1 diluted in sodium chloride.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 16Time frame: Week 16
Locations
41 sites in 9 countries. Site status is shown where the registry gives one.
InflaRX Investigational Site
Birmingham, Alabama
InflaRX Investigational Site
Fort Myers, Florida
InflaRX Investigational Site
Miami, Florida
InflaRX Investigational Site
Sandy Springs, Georgia
InflaRX Investigational Site
Dearborn, Michigan
InflaRX Investigational Site
Columbia, Missouri
InflaRx Investigational Site
Saint Joseph, Missouri
InflaRX Investigational Site
St Louis, Missouri
InflaRX Investigational Site
St Louis, Missouri
InflaRX Investigational Site
Chapel Hill, North Carolina
InflaRX Investigational Site
Cincinnati, Ohio
InflaRX Investigational Site
Hershey, Pennsylvania
InflaRx Investigational Site
Goodlettsville, Tennessee
InflaRX Investigational Site
Sofia, Bulgaria
InflaRX Investigational Site
Sofia, Bulgaria
InflaRX Investigational Site
Stara Zagora, Bulgaria
InflaRX Investigational Site
St. John's, Newfoundland and Labrador, Canada
InflaRX Investigational Site
Peterborough, Ontario, Canada
InflaRX Investigational Site
Richmond Hill, Ontario, Canada
InflaRX Investigational Site
Copenhagen, Denmark
InflaRX Investigational Site
Roskilde, Denmark
InflaRX Investigational Site
Paris, France
InflaRX Investigational Site
Nice, Alpes Maritimes, France
InflaRX Investigational Site
Bordeaux, Gironde, France
InflaRX Investigational Site
Toulouse, Haute Garonne, France
InflaRX Investigational Site
Antony, Hauts De Seine, France
InflaRX Investigational Site
Nantes, Loire Atlantique, France
InflaRX Investigational Site
Darmstadt, Hesse, Germany
InflaRX Investigational Site
Frankfurt am Main, Hesse, Germany
InflaRX Investigational Site
Bochum, North Rhine-Westphalia, Germany
InflaRX Investigational Site
Dessau, Saxony-Anhalt, Germany
InflaRX Investigational Site
Athens, Greece
InflaRX Investigational Site
Athens, Greece
InflaRX Investigational Site
Thessaloniki, Greece
InflaRX Investigational Site
Rotterdam, Netherlands
InflaRX Investigational Site
Gdansk, Poland
InflaRX Investigational Site
Kłodzko, Poland
InflaRX Investigational Site
Krakow, Poland
InflaRX Investigational Site
Lodz, Poland
InflaRX Investigational Site
Wroclaw, Poland
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.